Disparate Kinetics of Viable Virus Shedding in Immunocompromised Patients: SARS-CoV-2 Versus Influenza Virus-A Prospective Real-World Cohort Study.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 40971891.
- Also identified by DOI 10.1093/infdis/jiaf479.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
There are limited data comparing viral shedding between influenza and SARS-CoV-2 in immunocompromised patients. We prospectively enrolled 70 SARS-CoV-2 and 16 influenza patients, with 48 SARS-CoV-2 patients matched to 16 influenza patients by propensity score. Weekly collected respiratory samples were subjected to viral culture and antigen testing. In matched cohorts, the time to culture-confirmed viral clearance was shorter for influenza than SARS-CoV-2 (median, 4.5 vs. 29 days; adjusted hazard ratio [aHR] 27.5; P < .001), and antigen negativity occurred faster (3 vs. 23 days; aHR 19.2; P < .001). These findings show different clearance kinetics for influenza and SARS-CoV-2 in immunocompromised patients.
Medical subject headings
- Virus Shedding
- Immunocompromised Host
- COVID-19
- SARS-CoV-2
- Influenza, Human
- Orthomyxoviridae